Bio-Techne/$TECH

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Bio-Techne

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Ticker

$TECH
Primary listing

Industry

Life Sciences Tools and Services

Employees

3,100

ISIN

US09073M1045

Bio-Techne Metrics

BasicAdvanced
$8.4B
64.21
$0.83
1.46
$0.32
0.60%

What the Analysts think about Bio-Techne

Analyst ratings (Buy, Hold, Sell) for Bio-Techne stock.

Bulls say / Bears say

Bio-Techne delivered strong organic revenue growth with a 9% increase in Q2 and 6% in Q3 driven by robust demand in its Protein Sciences and Diagnostics & Spatial Biology segments.
Adjusted operating margin expanded to 34.9% in Q3 from 33.0% a year earlier, reflecting successful profitability initiatives and operational leverage.
Institutional investors are increasing stakes, with Price T. Rowe Associates boosting its holdings by 13.1% to 10.65 million shares in Q4 2024, underscoring confidence in Bio-Techne’s long-term prospects
Bio-Techne’s share price has fallen 38.5% from its 52-week high and declined 2.28% on July 15, marking three straight days of losses and signaling waning investor confidence.
Third quarter GAAP EPS dropped to $0.14 from $0.31 year-over-year, exposing volatility in core earnings and raising concerns about near-term profitability.
Citigroup cut its price target on Bio-Techne from $80 to $70 and R.W. Baird downgraded the rating to ‘hold’, highlighting analyst skepticism about the firm’s growth trajectory
Data summarised monthly by Lightyear AI. Last updated on 16 Jul 2025.

Bio-Techne Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Bio-Techne Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TECH

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs